Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Delea et al.

Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM, Ferrara A, Selby JV.

Diabetes Care. 2004 Mar;27(3):850-1; author reply 852-3. No abstract available.

PMID:
14988326
2.

Type 2 diabetes mellitus and heart failure.

Choy CK, Rodgers JE, Nappi JM, Haines ST.

Pharmacotherapy. 2008 Feb;28(2):170-92. doi: 10.1592/phco.28.2.170. Review.

PMID:
18225964
3.

Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data.

Macfarlane DP, Fisher M.

Am J Cardiovasc Drugs. 2006;6(5):297-304. Review.

PMID:
17083264
4.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147
5.

Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.

Patel RR.

Cardiol Rev. 2009 May-Jun;17(3):132-5. doi: 10.1097/CRD.0b013e31819faab2. Review.

PMID:
19384087
6.

[Heart failure with thiazolidinedione treatment: what do we know today?].

Erdmann E.

Dtsch Med Wochenschr. 2009 Jan;134(4):154-8. doi: 10.1055/s-0028-1123973. Review. German.

PMID:
19148858
7.

Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.

Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.

Pharmacotherapy. 2006 Feb;26(2):168-81. Review.

PMID:
16466323
8.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Review.

PMID:
18698014
9.
10.

Cardiovascular effects of the thiazolidinediones.

Qayyum R, Schulman P.

Diabetes Metab Res Rev. 2006 Mar-Apr;22(2):88-97. Review.

PMID:
16184618
11.

Heart failure in the diabetic patient.

Bell DS.

Cardiol Clin. 2007 Nov;25(4):523-38; vi. Review.

PMID:
18063157
12.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
13.

Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.

Donnelly R.

Int J Clin Pract. 2007 Jul;61(7):1160-9. Review.

PMID:
17511791
14.

[Diabetes mellitus and heart failure: epidemiology and therapy].

Pfister R, Erdmann E.

Herz. 2008 Apr;33(3):178-83. doi: 10.1007/s00059-008-3113-5. Review. German.

PMID:
18568311
15.
16.

Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.

Strowig SM, Raskin P.

Diabetes Obes Metab. 2005 Nov;7(6):633-41. Review.

PMID:
16219007
17.

Clinical inquiries. Do TZDs increase the risk of heart failure for patients with diabetes?

Baskin S, Neher JO, Dodson S, Hoffman R.

J Fam Pract. 2005 Aug;54(8):723-4. Review. No abstract available.

PMID:
16061064
18.

[Diabetes mellitus and heart failure - incidence and surgical therapy options].

Reiss N, Kleikamp G, Tenderich G, Tschöpe D, Körfer R.

Herz. 2008 Apr;33(3):206-10. doi: 10.1007/s00059-008-3116-2. Review. German.

PMID:
18568315
19.

Bone metabolism in type 2 diabetes and role of thiazolidinediones.

Vestergaard P.

Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):125-31. doi: 10.1097/MED.0b013e328325d155. Review.

PMID:
19300092
20.

[Therapy with glitazones--a risk for cardiovascular disease?].

Rottlaender D, Michels G, Erdmann E, Hoppe UC.

Dtsch Med Wochenschr. 2007 Dec;132(49):2629-32. Review. German.

PMID:
18050028
Items per page

Supplemental Content

Support Center